Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan

Abstract

Abstract Recent developments in diagnostic technology, accumulated clinical effort and established evidence have boosted early detection and drastically improved early and long‐term outcomes of gastric cancer. However, gastric cancer continues to be one of the most aggressive and life‐threatening malignancies among all cancers and is a global health problem. Between January 2017 and December 2018, various fascinating reports of managements and research were published, including the new 15th Japanese Classification of Gastric Carcinoma reflecting the 8th American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor, node and metastasis (TNM) classification (October 2017) and the new Gastric Cancer Treatment Guidelines version 5 (January 2018). Moreover, pivotal molecular features of gastric cancer were clarified by the worldwide cancer genome project, and various treatment targets and biomarkers such as circulating DNAs and microRNAs were detected. Novel treatment options using programmed cell death protein 1 immune checkpoint inhibitors have been started. In this review, we summarize the recent topics of classification, guidelines, and clinical and basic research in order to bring new insights to gastric cancer treatment.

Keywords

• biomarker
• gastric cancer
• Gastric Cancer Treatment Guidelines
• Japanese Classification of Gastric Carcinoma
• PD‐1 immune checkpoint inhibitor